Yes

Salicylate

Adjunctive treatment of tuberculosis used in combination with other antitubercular agents; has also been used in Crohn's disease

C

Hypersensitivity to aminosalicylate sodium

Use with caution in patients with hepatic or renal dysfunction, patients with gastric ulcer, patients with CHF, and patients who are sodium restricted

1% to 10%: Gastrointestinal: Nausea, vomiting, diarrhea, abdominal pain

<1%: Vasculitis, fever, skin eruptions, goiter with or without myxedema, leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, jaundice, hepatitis

Acute overdose results in crystalluria and renal failure, nausea, and vomiting

Alkalinization of the urine with sodium bicarbonate and forced diuresis can prevent crystalluria and nephrotoxicity

Decreased levels of digoxin and vitamin B₁₂

Aminosalicylic acid (PAS) is a highly specific bacteriostatic agent active against M. tuberculosis. Structurally related to para-aminobenzoic acid (PABA) and its mechanism of action is thought to be similar to the sulfonamides, a competitive antagonism with PABA; disrupts plate biosynthesis in sensitive organisms.

Absorption: Readily absorbed >90%

Metabolism: >50% acetylated in liver

Elimination: >80% excreted through kidneys as parent drug and metabolites; elimination is reduced with renal dysfunction

Oral:

Adults: 150 mg/kg/day in 2-3 equally divided doses (usually 12-14 g/day)

Dosing adjustment in renal impairment:

Cl_cr 10-50 mL/minute: Administer 50% to 75% of dose

Cl_cr <10 mL/minute: Administer 50% of dose

Administer after hemodialysis

May be administered with food

None reported

May cause bone marrow suppression; use caution with clozapine and carbamazepine

No information available to require special precautions

NSAID formulations are known to reversibly decrease platelet aggregation via mechanisms different than observed with aspirin. The dentist should be aware of the potential of abnormal coagulation. Caution should also be exercised in the use of NSAIDs in patients already on anticoagulant therapy with drugs such as warfarin (Coumadin®).

May be taken with food. Do not take tablets that are discolored (brown or purple); see pharmacist for new prescription. Do not stop taking without consulting prescriber. Report persistent sore throat, fever, unusual bleeding or bruising, persistent nausea or vomiting, or abdominal pain. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to be pregnant. Breast-feeding is not recommended.

Do not administer if discolored

Tablet: 500 mg

Davidson PT and Le HQ, "Drug Treatment of Tuberculosis - 1992," Drugs, 1992, 43(5):651-73.

"Drugs for Tuberculosis," Med Lett Drugs Ther, 1993, 35(908):99-101.

Iseman MD, "Treatment of Multidrug-Resistant Tuberculosis," N Engl J Med, 1993, 329(11):784-91.